The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 368 participants.
Also called NCT02008682
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 368 participants
- Sponsor
- Registry
-
NCT02008682
-
- Other papers using this trial's data
- Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT02008682. Randomized; no masking; primary purpose treatment. Start 2013-12 (registry gives no type); primary completion 2014-11 (actual). Results posted on 2015-12-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- liraglutide
- Intervention (Drug)
- sitagliptin
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct02008682- Content hash
18a4b05240486b0daff2415c058874f923c2f82eb969602fbf26f02f65bf4440